What Is Sunitinib (Sutent)? FDA Approval, Licensing in Türkiye, and Reimbursement Status
Reading tools
In this article
Sutent (Sunitinib) Profile
- FDA Approval: Yes (First approval: January 26, 2006)
- Brand Name: Sutent
- Active Ingredient: Sunitinib malate
- Administration: Oral (capsule taken by mouth)
- Class: Tyrosine kinase inhibitor (TKI)
- Category: Antineoplastic / Targeted therapy
- Manufacturer: Pfizer Inc.
- Availability in Türkiye: Licensed in Türkiye and covered by SGK.
- Approved Cancers:
- Metastatic renal cell carcinoma (RCC)
- Gastrointestinal stromal tumor (GIST), resistant or intolerant to imatinib
- Pancreatic neuroendocrine tumors (pNET)
What Is Sunitinib? How Does It Work?
Sutentis an oral targeted cancer medicine containing sunitinib malate. It is a tyrosine kinase inhibitor (TKI) used particularly for kidney cancer, GIST, and certain neuroendocrine tumors.
Mechanism of Action: Sutent blocks several tyrosine kinase enzymes required for cancer-cell growth and blood vessel formation around tumors (angiogenesis).
Main receptors targeted:
- VEGFR: Stops new blood vessel formation (angiogenesis).
- PDGFR: Prevents tumor spread into supporting tissues.
- c-KIT: Blocks the receptor driving GIST cell growth.
- FLT3, RET, and CSF-1R: Targets other critical kinases, making tumor survival harder.
FDA (US Food and Drug Administration) Approval History
- November 16, 2017: Approved in high-risk adult renal cell carcinoma patients for adjuvant treatment.
- May 20, 2011: Approved for a rare pancreatic cancer type (pNET).
- January 26, 2006: Received initial approvals for both GIST and advanced renal cell carcinoma (RCC).
- August 10, 2005: Pfizer submitted a new drug application to the FDA.
Licensing in Türkiye and Therapeutic Indications
Licensed Uses:
- For metastatic or locally advanced, inoperable disease with a Ki-67 index of 5 or below, showing progression by RECIST after somatostatin and one line of chemotherapy, in pancreatic neuroendocrine tumors .
- Treatment of imatinib-resistant metastatic/unresectable GIST or metastatic renal cell carcinoma.
Indications Usable Without Additional TİTCK Approval:
- Metastatic adenoid cystic carcinoma
- Advanced chondrosarcoma (after 1st-line treatment)
- Solitary fibrous tumor (2nd line and later)
- Alveolar soft part sarcoma
- Hemangiopericytoma (after 1st-line treatment)
- Advanced chordoma (after imatinib)
- Soft tissue sarcoma (after progression)
SGK Reimbursement and Pricing
Sunitinib is covered by SGK reimbursement in Türkiye.
December 2025 Pharmacy Retail Prices:
- Sutent 12.5 mg capsule: 13,657.15 TL
- Sutent 25 mg capsule: 27,185.39 TL
- Sutent 37.5 mg capsule: 40,713.66 TL
- Sutent 50 mg capsule: 27,185.08 TL
- Average cycle cost: 27,185.08- 40,713.66 TL.
Resistance Mechanisms
- Alternative Angiogenesis Pathways: Tumor cells activate bypass pathways such as FGF (fibroblast growth factor) .
- Target Kinase Mutations: Structural changes in VEGFR, c-KIT, or PDGFR receptors.
- Efflux Pumps: Increased P-glycoprotein (P-gp) pumps the drug out of cells.
- EMT and Stem Cells: Cells adopt a more aggressive phenotype, and resistant stem cells cause recurrence.
Pharmacokinetic Information
| Absorption | Bioavailability >50%. Time to Cmax: 6-12 hours. No food interaction. |
| Metabolism | Metabolized in the liver by CYP3A4 . Its main active metabolite, SU12662 , is at least as effective as the drug itself. |
| Half-Life | Sunitinib: 40-60 hours / SU12662: 80-110 hours. |
| Excretion | 60% is eliminated in feces and 15-20% in urine. |
Dosage and Treatment Regimens
- mRCC and GIST: 50 mg daily. Regimen: 4 weeks on treatment + 2 weeks off (4/2 cycle).
- pNET: 37.5 mg daily. Continuous (uninterrupted) daily use.
- Adjuvant RCC: 50 mg daily (4/2 regimen). Total 9 cycles (approximately 1 year).
Drug Interactions and Warnings
- CYP3A4 Inhibitors: Ketoconazole, erythromycin, and grapefruit juice increase blood drug levels and toxicity.
- CYP3A4 Inducers: Rifampicin, phenytoin, and dexamethasone may reduce efficacy.
- Cardiac: Arrhythmia risk increases with QT-prolonging drugs such as amiodarone.
- Other: Use caution with warfarin (bleeding risk) and levothyroxine (development of hypothyroidism).
Situations Requiring Attention
- Hypertension and the Heart: Blood pressure monitoring is essential; left ventricular function should be monitored.
- Hepatotoxicity: Check AST, ALT, and bilirubin regularly.
- Osteonecrosis of the Jaw: A dental examination is required before dental surgery.
- Wound Healing: Stop the drug at least 2 weeks before surgery.
- Thyroid: Monitor TSH for development of hypothyroidism.
Side Effects
- Diarrhea: 53%
- Fatigue: 51%
- Nausea: 45%
- Mucositis (mouth sores): 34%
- Hypertension: 30%
- Hand-foot syndrome: 28%
- Vomiting: 26%
- Taste disturbance: 25%
- Hypothyroidism: 21%
- Thrombocytopenia: 18%
- Bleeding: 8%
- QT prolongation: 4%
Important: Osteonecrosis of the jaw and RPLS syndrome may occur rarely (<1%). Monitor complete blood counts and liver tests during follow-up.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.